The emission tomographic imaging of activated microglia in the brain moves into the focus of neuroscientific research with increasing recognition of contributions of early inflammatory processes to neurodegenerative, traumatic, cancerous and infectious diseases of the brain. Whereas the mitochondrial isoform of the 18 kDa translocator protein (TSPO1) has been the main cellular target for positron emission tomography (PET) of this type of cells for decades, alternative marker proteins in the plasma membrane of microglia challenge efforts in ligand development, recently. The present report includes PET approaches using the chemokine receptor CX3CR1 and the FR2 folate C]ER176 presumed to reduce polymorphism-related inter-subject variations, with allosteric ligands for the chemokine receptor CX3CR1 and with radio labelled folate conjugates targeting the folate "cargo" receptor FR1 and the FR2 receptor characteristic for anti-inflammatory M2 microglia.
Introduction
The imaging of microglia as a marker of inflammation in traumatic, degenerative, neuropsychiatric and infectious brain diseases has been already for years a surrogate method for the monitoring of cerebral disorders [1] . The resting/surveying microglia in healthy tissue (resident macrophages of the brain) communicates with adjacent neurons and glia cells [2] . Cross talk between microglia and neurons is presumed to play an important role for synaptic plasticity [3] [4] [5] [6] [7] . Microglia can be activated by diverse molecules released during pathological alterations and reacts adopting different activated phenotypes [2] [8] [9] [10] [11] . Recently, microglial activation is regarded as one of the initial factors turning early acute metabolic and structural alterations into chronic processes.
Microglia acts as immune cell by survey of environmental and micro-environmental factors [5] [12] [13] [14] . The two extreme, functional kinds of possible phenotypes of activated microglia are M1 cells (classically activated, inflammatory) and M2 cells (alternatively activated, anti-inflammatory) [9] [15] .
For immunological approaches, such polarization of the functionality of microglia corresponds to the actions of the subsets of T helper cells (CD4 cells), Th1 and Th2 lymphocytes releasing the respective Th1-type and Th2-type cytokines as pro-inflammatory or anti-inflammatory response [10] [15] [16] .
Microglia accounts for 5% -10% of total glia cells of the human brain [10] [16] [17] and up to 20% in other mammalian species [18] [19] with lower percentage in the cortex and higher in corpus callosum. 30% -50% of cells in glioma are microglial cells; and glioma and astrocytoma are the most common brain tumors [20] .
Investigations of typical microglial cells are limited in vitro, because the source of this cell population in the brain is, as widely accepted, the yolk sac releasing a wave of primitive macrophages as progenitor cells of microglia during the early embryonal development [21] [22] [23] [24] . Microglial population colonizes the whole CNS and maintains itself by local proliferation [23] [24] .
A postnatal supplement of the resident cerebral microglial population by macrophages from the circulation is not very probably but also not completely out of discussion [24] [25] . As the normal functional state of microglia is accepted the resting (surveying) state [5] .
Currently, a multitude of structural markers is known allowing immunohistological phenotyping of microglia of different shapes, functions and locations [26] in vitro or ex vivo.
For in vivo imaging, one of the main targets investigated with PET or SPECT in microglial cells has been for many years mitochondrial TSPO1 (translocator protein 18 kDa), the former peripheral benzodiazepine binding sites (PBR) [27] , overexpressed in activated microglia. The target TSPO1 is a protein of the outer mitochondrial membrane [31] [32], more precisely, it is located at the contact sites between the outer and inner membrane [33] . Functional tasks of TSPO1 have been presumed in porphyrine transport, protein import, cholesterol transport, steroid biosynthesis, ion transport, cell proliferation and differentiation [34] [35] [36] . TSPO is found, especially, in cells with steroid synthesis. The evolutionary conserved protein is constituent of species from bacteria to mammals upstairs [37] . A 3D-crystal structure of bacterial as well as of mammalian TSPO has been pub- 
TSPO as PET Target
Already, during the 70 ties and 80 ties of the last century was recognized the 18 kDa translocator protein (TSPO; originally classified as peripheral benzodiazepine receptor = PBR) [32] is not restricted to peripheral organs, but also present in CNS, glial and ependymal cells. Although the densities of TSPO in the brain is a magnitude below that in kidney, heart, testis, ovary and uterus its increased expression in pathophysiological conditions like multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD) suggested a suitability as a biomarker of early stages of pathogenesis in inflammatory diseases or inflammation-related disorders [60] [61].
In subcellular fractions of brain extracts, the mitochondrial localization of TSPO1 was revealed [62] [63] [64] [65] . Later reports described a TSPO2 isoform in the plasma membrane during differentiation of erythrocytes [66] .
TSPO2 has been presumed also in nuclear membranes or close to nuclear membranes and in endoplasmic reticulum [35] . In contrast to TSPO1, it lacks in birds and mammals the isoquinoline-binding site [42] .
For evaluation of potential structure-activity-relationships (SAR) of TSPO1, close relations can be important with further mitochondrial proteins involved in energy production and mitochondrial homeostasis as part of the mPTP complex Currently, the first reports on the 3D structure of TSPO1 [40] promise also new insight on the oligomeric structures of the protein and potential relationships to other structures of the mitochondrial membrane.
Some TSPO ligands are supposed to bind rather to the multi protein complex than to single sub-proteins forming it.
An interesting contribution to understanding of subcellular compartmentation of TSPO has been provided, recently, by Yasin et al. [72] 3 H]PK11195 was with unlabelled PK11195 two orders of magnitude higher than with unlabelled Ro5-4864 [78] . The change from benzodiazepine lead structure to isoquinoline and quinoline promised markedly higher specificities.
2) Non-benzodiazepine, first generation ligands
The isoquinoline R-PK11195 [ Figure 2 ; (8) In spite of drawbacks in specificity, clinical investigations with [
revealed some interesting items on inflammatory processes in brain diseases.
Zhang [73] reviewed investigations using [ 
Second Generation Compounds
The small molecule TSPO ligands of the second generation, like FEPPA, FEMPA and DPA-714, AC5216 [ Figure 3 , (14)- (17)], DAA1106, FEDAA1106 [ Figure 3 ,
( (10), (11))], PBR111, vinpocetine or PBR06 and PBR28 [ Figure 3 ; ( (12), (13) Many of the second generation structures comprise three separate ring systems which promise differences in binding behavior in comparison to the first generation structures by innate conformational conditions in contrast to first generation structures. First studies with the crystal structure of TSPO included the first generation compound PK11195 [33] [39] as well as the second generation compound DAA1106 [40] and proposed for both substances the same binding site as for porphyrine. That supports rather the presumption that the change in the basic scaffold of the ring systems was less important for the binding properties of the compounds than the kind of substituents.
Some compounds, like FEDAA1106 and PBR06, form metabolites which can be a problem for the correct detection of microglial activation [73] [87].
Moreover, the inter-subject variations of these ligands are higher than for the first generation [72] . Responsible for these variations can be the rs6971 poly- These observations are a challenge to genotypic selection of patients for respective diagnostic imaging probes. Additionally, prerequisites for the use of Figure  3 , (11)] in seven AD patients (68 ± 3 years of age) and eight controls (69 ± 4 years) using, similar to Mabrouk's approach, a two-compartment model and Logan's analysis.
Possibly, the low size of the groups allowed no further evaluation and differentiation of HAB, MAB and LAB participants. The authors classified [ [88] whereas in the reports by Suridjan [89] [90] and Mabrouk [88] were included also people with severe cognitive impairment.
In postmortem tissue of frontal cortex of AD patients and controls, Venneti et al. [93] [ Figure 3 , (12)] a marked enhancement of TSPO labelling [94] . Moreover, Mirzaei et al. [94] described a good coincidence of binding of [ 
Third Generation Compounds and Recent Developments
Wadsworth et al. [95] and Chau et al. [96] investigated three further classes of compounds for their suitability as PET tracers of TSPO: diaryl anilides, tetracyclic and tricyclic scaffolds. As a first candidate compound among the tricyclic structures, was investigated GE-180 [ Figure 4 ( (18), (19) A study using a one-compartment model as well as two-compartment models for this tracer in healthy volunteers was published in the same year by Feeney et al. [97] . Feeney et al. [97] used the cortical grey matter as pseudo-reference region based on observations by Owen et al. [98] . The latter described a negligible binding of [ Ikawa et al. [102] reported that with the measurements with ER176, similarly like also for other tracers, differences in binding affinities related to genotypic In difference to other chemokine receptors and TSPO, is known only one endogenous CX3CR1 ligand.
Plasma Membrane Targets

CX3CR1 Chemokine Receptor
The CX3CR ligand FKN is a 373 a.a.r. membrane-bound polypeptide [49] , which is anchored in the cell membrane and supports the scavenging of leukocytes. The extracellular domain can be separated by tumor necrosis factor α converting enzyme (TACE) and is then present as a globular, extracellular polypeptide. By this way FKN is supposed to act as signaling peptide with inflammatory and homeostatic action as well.
The search for potential small molecule ligands of CX3CR1 has been realized by docking studies in homology models using the cytomegalovirus-encoded chemokine receptor homolog US28 [50] , however, to date with limited success.
Maciejewski-Lenoir et al. [111] Steen et al. [112] made the promiscuity of chemokine receptors for several peptide ligands responsible for the difficulties to develop effective small-molecule therapeutics targeting chemokine receptors. With regard to only one endogenous ligand, the CX3CR1 receptor provides better prerequisites than the most other chemokine receptors.
Small Molecule Ligands of CX3CR1
The use of microglial plasma membrane proteins as markers of activation or World Journal of Neuroscience proliferation earns not only attention because it could be applied to patients which are PET-negative due to TSPO polymorphisms.
A well accessible marker protein of the plasma membrane could allow also kinetics and dynamics of potential ligands with better feasibility for imaging purposes than an intracellular target like TSPO1.
The In 2015, Mease et al. [52] provided synthesis and first data of a 18 F-labelled PET tracer using AZD8797 as parent compound. FBTTP [ Figure 6 ; (29)] is the fluorine-18 labelled AZD8797 derivative [52] with a K i of 23 nM and 18fold selectivity Finally, there are several high-affinity small molecules with good selectivity to CX3CR1. The lipophilicity > 3.5 could be an obstacle for the use of these substances as PET tracers. However, the compounds are regarded as potentially useful drugs in multiple sclerosis and provide lead structures for development of potential PET tracers with better pharmacokinetic properties.
Folate Receptors
Antifolates play a key role in therapies of cancer and rheumatic diseases since many decades. Folic acid is an essential part of the carbon-one metabolism. Because it is not synthesized in mammalian cells, it has to be obtained as Vitamin B9 dietary compound.
Four membrane proteins have been described to be involved into the uptake of folate [ Figure 7 , (31)] and of 5-methyltetrahydrofolate (5-MTHF) occurring in the liver after intestinal uptake of folic acid [115] .
The proton-coupled folate transporter (PCFT) [116] , highly expressed in small intestinum, is responsible for uptake of folate into the epithelium at low pH. have been described [120] , which should be of relevance when folic acid decreases to nanomolar concentrations in blood serum [118] . Homologies between the receptor isoforms are high with only small differences in the pharmacodynamically relevant structures. However, FR3 is a soluble receptor and, recently, a role of FR1 was described as a transcriptionally relevant protein, which may interact with nuclear structures following internalization [121] [122].
Blockage of the cerebral folate receptors and of the uptake across the blood brain barrier is known to cause marked folic acid deficiency in the brain [123] resulting in epileptic symptoms, which can be, potentially, reversed by folic acid application.
FR1, is localized in epithelial cells, kidney, lung and also in the choroid plexus.
It is the most widely distributed subtype of the folate receptors. However, its World Journal of Neuroscience density is low, with exception of high expression in some tumors [117] . In general, folate receptor expression is typical for cells with functions in embryonic development [58] .
FR2 is expressed in the cells of the hematopoetic system, in placenta, in spleen and thymus [117] [120] and has been mentioned as overexpressed with some specificity in anti-inflammatory macrophages/microglia [124] [58] and to potential markers of glial activation in inflammatory diseases.
Potential FR2 Ligands for PET Tomographic Imaging
To date, most efforts for the development of ligands at FR2 receptors suitable for radio-imaging have been reported on SPECT tracers [126] . One report potentially interesting also for the analysis of cerebral microglia has been provided by Jager et al. [126] Overexpression of FR2 in the prefrontal cortex of rats was demonstrated, recently, in a model of acute and chronic stress [48] in parallel with other M2 microglial markers.
Brain uptake of folic acid, 5MTFH and methotrexate was first suggested by the results of a study by Spector and Lorenzo 1975 [128] . Since this time, it is known choroid plexus binds the major part of folic acid achieving its cells. Spector and Lorenzo [128] [54] .
Synthesis of folate conjugates using diverse prosthetic groups was the method of choice, already years ago, because direct fluorination of folic acid was not possible.
Bettio et al. [130] synthesized a folate tracer using 4-fluorobenzylamine (FBA) as prosthetic group with region selective linkage to the α-and to the γ-carbonyl group of folic acid [ Figure 7 , (31) 
Summary and Conclusions
Visualization of microglial activities as a key factor in pathogenesis and progres- [140] .
New insights on protein-ligand interactions and protein-protein relationships in the mitochondrial membrane can be expected now also from molecular dynamics studies using the crystal structure of TSPO [38] [39] [40] . This should offer not only new information on the physiological and pathophysiological role of TSPO in inflammatory diseases but also on potential protective mechanisms in infectious diseases like malaria [66] .
For the PET targets on the plasma membrane, CX3CR1 and FR2, polymorphisms of relevance for the imaging results, similar to that of second generation ligands of TSPO, are not known, currently. CX3CR1 ligands proposed recently by Karlström et al. [109] showed appropriate binding affinities and selectivity. Their high lipophilicity was a tribute to their original purpose as an orally applicable therapeutic in multiple sclerosis. With regard to the application as a PET tracer it is rather a drawback. AZD8797 as well as related derivatives open a door for further modifications of potential lead structures.
Hitherto, small molecule ligands or folate conjugates binding to FR1 and FR2 specifically are not available. A PET labelling of folate receptors in inflammatory processes becomes specific for the FR2 subtype only by the distribution of the FR2-expressing M2 subtype of activated microglia.
On the other hand, distribution of FR1 and FR2 as well as their contributions to the cerebral uptake of folate through the epithelial cells of the choroid plexus and from the ventricular or spinal cerebrospinal fluid raise new questions also for potential imaging applications apart from tumor diseases. Additionally, the time course of such processes and their role in comparison to a direct transfer of folate, folate conjugates and analogues across the blood vessels would be an important item for the estimation of a potential diagnostic value of FR ligands in clinical PET imaging methods. Moreover, the recognition that the permeability of the blood brain barrier increases with rising age earns some attention [141] .
